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ABSTRACT
Objective: To examine the effectiveness of systemic chemotherapy following 
radical hysterectomy for women with intermediate-risk stage IB cervical cancer.
Materials and Methods: This is a retrospective analysis of a previously organized 
nation-wide cohort study examining 6,003 women with stage IB-IIB cervical cancer who 
underwent radical hysterectomy between 2004 and 2008 in Japan. Survival of 555 women 
with stage IB cervical cancer in the intermediate-risk group (deep stromal invasion > 50%, 
large tumor size > 4 cm, and lympho-vascular space invasion [LVSI]) were examined 
based on adjuvant therapy patterns: chemotherapy alone (n = 223, 40.2%), concurrent 
chemo-radiotherapy (n = 172, 31.0%), and radiotherapy alone (n = 160, 28.8%).
Results: The most common intermediate-risk pattern was LVSI with deep stromal 
invasion (n = 216, 38.5%). The most common chemotherapeutic choice was taxane/
platinum (52.2%). Women with adenocarcinoma/adenosquamous histology were 
more likely to receive chemotherapy (P = 0.03), and intermediate-risk pattern was 
not associated with chemotherapy use (P = 0.11). Women who received systemic 
chemotherapy had disease-free survival (5-year rate, 88.1% versus 90.2%, adjusted-
hazard ratio (HR) 0.98, 95% confidence interval (CI) 0.52–1.83, P = 0.94) and cause-
                                                     Research Paper
Oncotarget106867www.impactjournals.com/oncotarget
specific survival (95.4% versus 94.8%, adjusted-HR 0.85, 95% CI 0.34–2.07, P = 
0.71) similar to those who received concurrent chemo-radiotherapy on multivariable 
analysis. Similar results were seen among 329 women with multiple intermediate-
risk factors (5-year rates for disease-free survival, chemotherapy versus concurrent 
chemo-radiotherapy, 87.1% versus 90.2%, P = 0.86; and cause-specific survival 
94.6% versus 93.4%, P = 0.82). Cumulative local-recurrence (P = 0.77) and distant-
recurrence (P = 0.94) risks were similar across the adjuvant therapy types.
Conclusions: Our study suggests that systemic chemotherapy may be an alternative 
treatment choice for adjuvant therapy in intermediate-risk stage IB cervical cancer.
INTRODUCTION
Worldwide, cervical cancer was the most common 
gynecologic malignancy in 2012 [1]. When the gross 
tumor is confined to the cervix, surgery remains the 
mainstay of treatment, consisting of radical hysterectomy 
and pelvic lymphadenectomy [2]. Hysterectomy 
specimens are useful to identify certain tumor factors 
associated with an increased risk of disease recurrence. 
Historically, these surgical-pathological risk factors are 
grouped into high-risk and intermediate-risk [3–5], and 
tumor factors in the intermediate-risk group include a 
large tumor size, deep stromal invasion, and lympho-
vascular space invasion (LVSI). 
Per the current guidelines set forth by multiple 
societies, women with early-stage cervical cancer in the 
intermediate-risk group are recommended to receive 
postoperative pelvic radiotherapy after surgical treatment 
in order to reduce the risk of recurrence [6, 7]. While the 
survival benefit of this adjuvant radiotherapy is supported 
by level I evidence [4], there is a concern for adverse 
events related to radiotherapy including genitourinary, 
hematologic, and gastrointestinal complications [8]. 
Due to these toxicity profiles of radiotherapy 
use, systemic chemotherapy has been considered as an 
alternative treatment option for adjuvant therapy after radical 
hysterectomy for women in the intermediate-risk group 
[9–12]. While some studies have suggested the possible 
utility of systemic chemotherapy, they were conducted with 
a relatively small sample size or with a lack of an appropriate 
control arm making their results difficult to interpret.
The objective of this study was to examine survival 
outcomes of women with intermediate-risk stage IB cervical 
cancer who received postoperative systemic chemotherapy 
following radical hysterectomy, and compare these outcomes 
to those women who received radiation-based therapy.
RESULTS
The selection schema is shown in Figure 1. 
Among 6,003 cases in the study cohort, there were 555 
cases which met the eligibility criteria for this analysis. 
Adjuvant therapy patterns included systemic chemotherapy 
(n = 223), concurrent chemo-radiotherapy (CCRT) (n = 172), 
and radiotherapy (RT) alone (n = 160). 
In the chemotherapy group (Supplementary Table 1), 
the most common chemotherapy choice was a taxane/
platinum-doublet (52.9%) followed by irinotecan-based 
regimens (19.7%). The median number of administered 
chemotherapy cycles was 4, and 32.3% received 6 
cycles of chemotherapy. The majority of chemotherapy 
was administered with a 4-week time interval (61.9%). 
Chemotherapy delay was seen in 37 (16.6%) cases with 
hematological toxicity being the most common reason 
for this delay (n = 25, 67.6%). Treatment delay was 
more common among women who received > 3 cycles 
compared to those who received ≤ 3 cycles (23.7% versus 
10.6%, P = 0.017). There were 23 (10.3%) cases with 
chemotherapy discontinuation in this study population. 
In the CCRT group (Supplementary Table 2), the most 
common radio-sensitizer was cisplatin (n = 88, 51.2%) 
followed by nedaplatin (n = 54, 31.4%). 
Patient demographics across the three groups are 
shown in Table 1. Patient age at diagnosis was similar across 
the groups (P = 0.18), and the year of diagnosis was not 
associated with chemotherapy use (P = 0.36). Women with 
adenocarcinoma / adenosquamous histology were more 
likely to receive chemotherapy compared to other treatment 
options: 52.9% for the chemotherapy group, 24.4% for the 
CCRT group, and 25.6% for the RT group (P < 0.001). 
Women who received chemotherapy had a lower frequency 
of tumor with deep stromal invasion compared to the other 
modalities (P = 0.02). The frequency of large tumors and 
LVSI were similar across the three groups (both, P > 0.05). 
Women in the CCRT group had the lowest pelvic lymph 
node counts among the three groups whereas women in the 
RT alone had had the lowest para-aortic lymph node counts 
among the three groups (both, P < 0.05).
The most common intermediate-risk factor was 
LVSI (n = 427, 76.9%) followed by deep stromal invasion 
(n = 392, 70.6%) and large tumor size (n = 125, 22.5%). 
When cases were stratified by the combination of 
intermediate-risk factors in the whole cohort, tumors with 
LVSI and deep stromal invasion was the most common 
pattern (n = 214, 38.6%) followed by LVSI alone (n = 131, 
23.6%) and deep stromal invasion alone (n = 85, 15.3%). 
There were 63 (11.4%) cases that had all three of these 
intermediate-risk factors.
Survival analysis was performed and the median 
follow-up time of women without survival events was 
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5.5 years. There were 62 recurrences and 30 deaths 
due to cervical cancer identified in this study. There 
were no deaths related to complications from adjuvant 
chemotherapy or radiotherapy in the cohort. On 
univariable analysis, adjuvant treatment types were not 
associated with disease-free survival (5-year rates, 88.0% 
for chemotherapy group, 90.2% for CCRT group, and 
89.8% for RT group, P = 0.90; Figure 2A). When the 
association of adjuvant therapy and disease-free survival 
was adjusted for other covariates on multivariable models 
(Table 2), chemotherapy use and CCRT did not differ in 
disease-free survival (adjusted-hazard ratio (HR) 0.98, 
95% confidence interval (CI) 0.52 to 1.84, P = 0.95). The 
systemic chemotherapy group had a similar disease-free 
survival compared to the RT alone group on adjusted 
models (data not shown).
Similarly, adjuvant treatment types were not 
associated with cause-specific survival (5-year rates, 
95.3% for chemotherapy group, 94.8% for CCRT group, 
and 94.8% for RT group, P = 0.99; Figure 2B). After 
adjusting for other covariates for cause-specific survival 
in multiple models (Table 3), chemotherapy use was 
not associated with cause-specific survival compared to 
CCRT (adjusted-HR 0.85, 95% CI 0.34 to 2.08, P = 0.71). 
Likewise, cause-specific survival was similar between the 
systemic chemotherapy group and the RT alone group on 
adjusting models (data not shown). 
When survival was compared between CCRT 
and RT alone groups, women who received CCRT had 
disease-free survival (adjusted-HR 1.00, 95% CI 0.53 
to 1.90, P = 0.99) and cause-specific survival (adjusted-
HR 0.82, 95% CI 0.34 to 2.01, P = 0.67) similar to those 
who received RT alone. Among women who received 
adjuvant chemotherapy, the number of administered 
cycles was not associated with disease-free survival 
(5-year rate, 3 versus 6 cycles, 89.4% versus 89.6%, 
P = 0.84) and cause-specific survival (97.4% versus 
92.9%, P = 0.38). Chemotherapy treatment delay was 
significantly associated with decreased disease-free 
survival (70.8% versus 91.9%, P = 0.001).
Among women who developed recurrent disease 
(median follow-up time after recurrence 42.6 months for 
censored cases and 15.3 months for deceased cases), the 
second remission rates after salvage intervention were 
Figure 1: Study selection schema. *Including unknown lymph node status. †Including unknown neoadjuvant therapy status. ‡Including 
no adjuvant therapy status. Abbreviations: JGOG, Japanese Gynecologic Oncology Group; unk, unknown; RT, radiotherapy; and CCRT, 
concurrent chemo-radiotherapy.
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statistically similar across the three groups:  CCRT group 
20%, chemotherapy alone group 30.8%, and 25% for RT 
alone group (P = 0.77).
There were 326 cases in which the tumor exhibited 
at least two intermediate-risk factors (chemotherapy alone 
n = 114, CCRT n = 117, and RT alone n = 95). In this 
sub-group the results were similar to the whole cohort, 
and adjuvant therapy was not associated with disease-
free survival (5-year rates, 86.9% for chemotherapy 
group, 90.2% for CCRT group, and 85.9% for RT group, 
Table 1: Patient demographics (N = 555)
Characteristics CCRT Chemotherapy RT alone P-value
No. n = 172 n = 223 n = 160  
Year 0.36
   2004 27 (15.7%) 30 (13.5%) 33 (20.6%)
   2005 26 (15.1%) 44 (19.7%) 28 (17.5%)
   2006 39 (22.7%) 40 (17.9%) 28 (17.5%)
   2007 48 (27.9%) 57 (25.6%) 33 (20.6%)
   2008 32 (18.6%) 52 (23.3%) 38 (23.8%)  
Age (mean ±SD) 46.0 (±10.9) 45.3 (± 11.0) 47.5 (± 12.8) 0.18
Stage 0.32
   IB1 130 (75.6%) 181 (81.2%) 130 (81.3%)
   IB2 42 (24.4%) 42 (18.8%) 30 (18.8%)
Histology < 0.001
   Squamous 130 (75.6%) 105 (47.1%) 119 (74.4%)
   Adenocarcinoma 33 (19.2%) 79 (35.4%) 25 (15.6%)
   Adenosquamous 9 (5.2%) 39 (17.5%) 16 (10.0%)
Deep stromal invasion 0.02
   No 439 (22.7%) 879 (35.4%) 45 (28.1%)
   Yes 133 (77.3%) 144 (64.6%) 115 (71.9%)  
Tumor size 0.13
   ≤ 4.0 cm 125 (72.7%) 181 (81.2%) 124 (77.5%)
   > 4.0 cm 47 (27.3%) 42 (18.8%) 36 (22.5%)
LVSI 0.75
   Not present 37 (21.5%) 55 (24.7%) 36 (22.5%)
   Present 135 (78.5%) 1768 (75.3%) 124 (77.5%)  
Sampled lymph nodes 
   Pelvic (median IQR) 26 (16) 31 (20) 30 (18) 0.001
   Para-aortic (median IQR)* 7 (8) 8 (9) 5 (7) 0.045
Risk factor patterns 0.09
   Deep stroma alone 25 (14.5%) 35 (15.7%) 25 (15.6%)
   Size alone 2 (1.2%) 7 (3.1%) 4 (2.5%)
   LVSI alone 28 (16.3%) 67 (30.0%) 36 (22.5%)
   Deep stroma + size 10 (5.8%) 13 (5.8%) 7 (4.4%)
   LVSI + deep stroma 72 (41.9%) 79 (35.4%) 63 (39.4%)
   LVSI+ size 9 (5.2%) 5 (2.2%) 5 (3.1%)
   All 3 factors 26 (15.1%) 17 (7.6%) 20 (12.5%)
Mean (± SD), median (interquartile range), or number (%) per column are shown. One-way ANOVA test, chi-square test, or 
Kruskal-Wallis H test for P-values. *Performed in 15 cases in CCRT group, 34 cases in chemotherapy group, and 30 cases for 
RT group, respectively. Abbreviations: IQR, interquartile range; CCRT, concurrent chemoradiotherapy; and LVSI, lympho-
vascular space invasion.
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Figure 2: Survival curves based on adjuvant treatment types. Log-rank test for adjusted P-values. Survival curves based on 
adjuvant therapy types are shown for: (A) disease-free survival and (B) cause-specific survival. Abbreviations: CCRT, concurrent chemo-
radiotherapy; and RT, whole pelvic radiotherapy alone.
Table 2: Adjusting models for disease-free survival and adjuvant therapy (N = 555)
Age Age, histology Age, histology, risk factors
Characteristics No. HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Adjuvant type  
   CCRT 172 1 1 1
   Chemotherapy alone 223 1.08 (0.59–1.98) 0.81 0.89 (0.48–1.66) 0.71 0.98 (0.52–1.84) 0.95
   RT alone 160 0.95 (0.48–1.86) 0.88 0.93 (0.47–1.83) 0.83 0.98 (0.50–1.93) 0.95
Age
   < 50 years 342 1 1 1
   ≥ 50 years 213 0.75 (0.43–1.29) 0.329 0.76 (0.44–1.31) 0.32 0.75 (0.44–1.30) 0.31
Histology  
   SCC 354 1 1
   Non-SCC 201 1.91 (1.12–3.26) 0.017 2.06 (1.21–3.51) 0.008
Deep stromal invasion
   No 163 1
   Yes 392 1.31 (0.74–2.33) 0.36
Tumor size
   ≤4.0 cm 430 1
   >4.0 cm 125 1.20 (0.64–2.25) 0.56
LVSI
   Not present 128 1
   Present 427 3.91 (1.54–9.95) 0.004
An association of adjuvant treatment type and survival outcome was adjusted by survival factors in Cox proportional-hazards 
regression models. Three models were tested as above. Significant P-values were emboldened. Abbreviations: HR, hazard 
ratio; CI, confidence interval; CCRT, concurrent chemo-radiotherapy; RT, radiotherapy; SCC, squamous cell carcinoma; and 
LVSI, lympho-vascular space invasion.
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P = 0.86) and cause-specific survival (5-year rates, 94.5% 
for chemotherapy group, 93.4% for CCRT group, and 
92.2% for RT group, P = 0.84). Among 229 cases in which 
the tumor had only one single intermediate-risk factor, LVSI 
alone had the lowest disease-free survival compared to other 
factors although it did not reach statistical significance (5-
year rate, 87.8% for LVSI alone, 94.8% for deep stromal 
invasion alone, and 100% for large tumor alone, P = 0.11).
Patterns of recurrence were examined, and local 
recurrence was seen in 29 cases including 6 cases of 
vaginal cuff recurrence, while distant recurrence was seen 
in 33 cases. Adjuvant treatment type was not associated 
with local recurrence (5-year rates, 5.4% for chemotherapy 
group, 4.4% for CCRT group, and 6.4% for RT group, 
P = 0.79; Figure 3A) and distant recurrence (5-year rates, 
5.9% for chemotherapy group, 5.4% for CCRT group, and 
5.1% for RT group, P = 0.93; Figure 3B).
Results of propensity score matching are shown in 
Supplementary Table 3. There were no difference in clinico-
pathological factors between the CCRT group and the 
chemotherapy group (all, P > 0.05). Women who received 
postoperative chemotherapy had disease-free survival (5-year 
rates, 90.4% versus 89.6%, HR 0.75, 95% CI 0.32 to 1.79, 
P = 0.52) and cause-specific survival (90.4% versus 89.6%, 
HR 0.79, 95% CI 0.21 to 2.92, P = 0.72) similar to those who 
received CCRT. 
DISCUSSION
The key finding of the study is that systemic 
chemotherapy use was associated with comparable survival 
compared to radiotherapy-based treatment in women with 
stage IB cervical cancer and at least one intermediate-risk 
factor and without a high risk factor. Moreover, our study 
found that women who had a single intermediate-risk 
factor with LVSI alone had a survival outcomes similar to 
those who had multiple intermediate-risk factors.
The effectiveness of systemic chemotherapy as 
an adjuvant therapy in early-stage cervical cancer in the 
intermediate-risk group has not been completely studied, 
and definitive treatment recommendations are currently 
lacking. Our study findings are similar to prior studies 
that demonstrated comparable survival outcomes between 
systemic chemotherapy and CCRT as adjuvant therapy [9, 
11]. Because these prior studies were small in sample size 
(38–47 cases for chemotherapy), our study is more definitive 
to clarify this association (223 cases for chemotherapy). 
Therefore, we can respectfully state that postoperative 
chemotherapy may be as effective as radiation-based therapy. 
To date, “classic” criteria of the intermediate-risk 
group in cervical cancer per the NCCN guidelines require 
at least two out of the three factors (deep cervical stromal 
invasion, large tumor, and LVSI) [6]. However, other 
societies suggest different criteria [13], and the Japan 
Society of Gynecologic Oncology (JSGO) the intermediate-
risk group if any one of the three factors is present in the 
tumor [7]. We therefore followed the JSGO criteria and 
included the cases of stage IB cervical cancer with any risk 
factors as above. However, when we adopted the National 
Comprehensive Cancer Network (NCCN) guidelines and 
analyzed a subgroup of cases with multiple risk factors, 
similar results were demonstrated and chemotherapy use 
had similar survival outcomes compared to radiotherapy.
Of interest, women whose tumor exhibited only 
LVSI had survival outcomes similar to those with 
multiple risk factors (5-year disease-free survival rate for 
LVSI alone versus multiple risk factors, 87.9% versus 
85.9–90.2%). Recurrence risks were minimal when 
tumors exhibited only large size or deep cervical stromal 
invasion (5-year disease-free survival 94.8% and 100%, 
Figure 3: Cumulative incidence curves based on adjuvant treatment types. Log-rank test for adjusted P-values. Cumulative 
incidence curves based on adjuvant therapy types are shown for: (A) loco-regional recurrence and (B) distant recurrence. Abbreviations: 
CCRT, concurrent chemo-radiotherapy; and RT, whole pelvic radiotherapy alone.
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respectively). Therefore, LVSI alone may need to be 
considered as an intermediate-risk factor. Further study to 
validate and prove our results is warranted. 
In a sensitivity analysis, we examined survival 
outcome of women who received CCRT compared to 
RT alone. The current guidelines for the intermediate-
risk group recommend whole pelvic radiotherapy alone 
without concurrent administration of chemotherapy, 
and the use of CCRT is optional [6, 7]. In review of the 
literature, there were multiple cohort studies examined the 
effectiveness of CCRT over RT alone for the intermediate-
risk group [14, 15], suggesting improved survival with 
CCRT use. Conversely, other investigators concluded 
that CCRT does not improve survival when compared 
to radiotherapy alone in the intermediate-risk group 
[16]. Our study also did not demonstrate a difference in 
survival between CCRT and RT alone groups. Currently, 
there is an ongoing phase III randomized controlled 
trial comparing CCRT versus RT alone in women with 
surgically treated intermediate-risk early-stage cervical 
cancer (GOG-263) [17]. The estimated time for the 
completion of accrual is December 2020, and this trial 
will ultimately answer the utility of CCRT for this patient 
population. 
The benefit of offering systemic chemotherapy 
over radiotherapy is to minimize complications from 
pelvic irradiation administered after radical pelvic 
surgery. This rationale was based on a general consensus 
that demonstrated high complication rates with pelvic 
irradiation after radical hysterectomy compared to 
surgery alone [18]. In the intermediate-risk group, one 
prior retrospective study reported a higher adverse event 
rate in the CCRT group compared to the chemotherapy 
group [11]. Our study did not have information to assess 
postoperative complications. To date, there is no head-
to-head trial directly comparing efficacy and adverse 
events between adjuvant chemotherapy and radiotherapy 
in intermediate-risk early-stage cervical cancer. In Japan, 
JGOG is going to launch a phase III trial comparing 
adjuvant chemotherapy and CCRT in women with high-
risk stage IB-IIB cervical cancer (AFTER trial). Although 
the patient population is not an intermediate-risk group, 
this trial will answer the question regarding the adverse 
event related to adjuvant therapy.
Strengths of the study included a sample size that 
is one of the largest in the literature. In addition, the 
dataset is considerably clear with our rigorous inclusion 
and exclusion criteria, making interpretation of the results 
Table 3: Adjusting models for cause-specific survival and adjuvant therapy (N = 555)
Age Age, histology Age, histology, risk factors
Characteristics No. HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Adjuvant type  
   CCRT 172 1 1 1
   Chemotherapy alone 223 1.03 (0.43–2.44) 0.95 0.85 (0.34–2.08) 0.71 1.02 (0.41–2.54) 0.96
   RT alone 160 1.05 (0.42–2.64) 0.92 1.03 (0.41–2.59) 0.95 1.13 (0.44–2.85) 0.80
Age
   < 50 years 342 1 1 1
   ≥ 50 years 213 0.77 (0.36–1.65) 0.50 0.79 (0.37–1.68) 0.54 0.81 (0.38–1.73) 0.659
Histology  
   SCC 354 1 1
   Non-SCC 201 1.85 (0.87–3.892) 0.11 2.17 (1.02–4.62) 0.045
Deep stromal invasion
   No 163 1
   Yes 392 1.02 (0.47–2.21) 0.97
Tumor size
   ≤ 4.0 cm 430 1
   > 4.0 cm 125 2.879 (1.29–6.00) 0.009
LVSI
   Not present 128 1
   Present 427 11.4 (1.52–84.8) 0.018
An association of adjuvant treatment type and survival outcome was adjusted by survival factors in Cox proportional-hazards 
regression models. Three models were tested as above. Abbreviations: HR, hazard ratio; CI, confidence interval; CCRT, 
concurrent chemo-radiotherapy; RT, radiotherapy; SCC, squamous cell carcinoma; and LVSI, lympho-vascular space invasion.
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more reliable. However, there are multiple limitations 
in this study. First, this is a retrospective study that may 
miss confounding factors in the analysis. For example, we 
do not know the treatment allocation for chemotherapy 
versus other treatment types. Indeed, there are various 
practice patterns for adjuvant therapy in intermediate-
risk early-stage cervical cancer in Japan [19], and this can 
be a major drawback of the study resulting in selection 
bias. Second, there are multiple chemotherapy regimens 
and administered cycles used in the chemotherapy group 
(heterogeneity), and we were not able to recommend any 
specific chemotherapy choice over others.
Weaknesses of the study included that our study 
population had a fairly favorable survival outcome 
with the limited number of survival events despite the 
adequate median follow-up of more than five years. For 
this reason, an adjustment model with five covariates for 
cause-specific survival may result in over-adjustment 
given the number of cervical cancer mortality events. 
However, two other adjustment models for cause-specific 
survival were consistent to support the current findings, 
and this association of chemotherapy and cause-specific 
survival is likely true. While central pathology review 
was not performed to confirm that intermediate-risk 
criteria was met, these surgical-pathological factors are 
well-established histopathological findings and thus 
inter-observer-variability is less likely to differ across the 
pathologists. 
The intermediate-risk criteria for deep stromal 
invasion was recorded as outer versus inner half and tumor 
size was recorded for > 4 versus ≤ 4 cm in this surgical 
database per the JSGO criteria, and thus, we were not 
able to apply the Gynecologic Oncology Group (GOG) or 
Korean criteria for the intermediate-risk in cases where the 
depth of invasion was defined as outer third [4, 20].  In this 
study, we used the JSGO criteria because this study was 
conducted in the society designated institutions and the 
validation of the society criteria has not been tested in large-
scale study population. However, when we examined the 
cases with any two or more risk factors, survival outcome of 
our study population seems comparable to that seen in the 
GOG-92 trial (2-year disease-free survival rate 88%) [4]. 
In summary, our study suggests that systemic 
chemotherapy can be an alternative effective treatment 
choice as adjuvant therapy for women with intermediate-
risk stage IB cervical cancer. This option can be 
particularly suitable in patients who are not the best 
candidates for radiotherapy such as those with pelvic 
adhesive disease, intraoperative abdomino-pelvic 
injury, radiation intolerance, and non-compliance for 
the radiation treatment schedule. Moreover, because 
increased chemotherapy cycles did not improve survival, 
and women in the intermediate-risk group have a generally 
good prognosis, the utility of a reduction in the number of 
chemotherapy cycles may be considered to minimize the 
toxicity of chemotherapy. Finally, the current intermediate-
risk criteria per the JSGO guidelines need to be revised, 
as the present criteria may result in overtreatment in cases 
where the prognosis is generally favorable. Based on our 
results, at least two risk factors as well as LVSI alone may 
meet criteria for stratification into the intermediate-risk 
category. Establishing stricter criteria weighing treatment 
benefits and risks are warranted.
MATERIALS AND METHODS
Eligibility
This was a retrospective analysis of the previously 
organized nation-wide large-scale observational study 
conducted in 116 Japanese Gynecologic Oncology Group 
(JGOG) designated institutions [20–22]. We collected 
consecutive cases of women with stage IB-IIB cervical 
cancer who underwent a radical hysterectomy between 
January 1, 2004 and December 31, 2008. The study period 
for the data acquisition was between October 1, 2012 and 
February 28, 2013. Institutional Review Board approval 
was obtained at Tottori University, which served as the 
host institution, and JGOG-participating institutions 
reviewed the protocol and obtained Institutional Review 
Board approval as indicated. 
Eligibility criteria for this study were women with 
stage IB cervical cancer who met criteria for intermediate-
risk disease, and received adjuvant therapy following type 
III radical hysterectomy and pelvic lymphadenectomy. 
Per the JSGO treatment guidelines for cervical cancer, 
the intermediate-risk group is defined as cervical cancer 
in which the tumor is confined to the cervix without 
parametrial or lymph node involvement, and exhibits any 
one of the following three factors: large cervical tumor 
> 4 cm, deep cervical stromal invasion (outer half), and 
LVSI [7]. We limited the histology types only to squamous 
cell carcinoma, adenocarcinoma, and adenosquamous for 
comparison with a prior study [4]. Women were excluded 
from the study if high-risk criteria were present (pelvic 
lymph node metastasis, parametrial tumor involvement, 
and surgical margin tumor involvement) or if no surgical-
pathological risk factor was identified. We also excluded 
women with tumor involving in para-aortic lymph 
nodes, ovaries, or uterine corpus. Women who received 
neoadjuvant therapy, unknown adjuvant therapy, or 
received a battery of both systemic chemotherapy and 
radiotherapy were also excluded. 
Clinical information
Clinical and tumor information abstracted from 
medical and pathological records included age, histologic 
subtype, clinical and pathological stages, tumor size, 
pelvic and para-aortic lymph node status (including the 
number sampled), parametrial involvement, deep stromal 
invasion, LVSI, uterine corpus involvement, ovarian 
Oncotarget106874www.impactjournals.com/oncotarget
involvement, and the presence of distant metastasis. 
Adjuvant treatment information included the following 
three modalities: concurrent chemo-radiotherapy with 
pelvic irradiation and weekly chemotherapy (CCRT 
group), systemic chemotherapy alone (chemotherapy 
group), and whole pelvic radiotherapy alone (RT group). 
Among women who received chemotherapy, the type of 
chemotherapy,  the number of administered cycles, and 
toxicity were recorded.
Survival information included disease-free and 
cause-specific survival. Disease-free survival was defined 
as the time interval between the hysterectomy and the first 
recurrence. Cause-specific survival was defined as the time 
interval between the hysterectomy date and death due to 
cervical cancer. The patients were censored if patients 
were alive at the last follow-up or had died due to another 
cause. Among women who developed recurrent disease, 
locations of recurrence were grouped into local recurrence 
(vaginal cuff and/or pelvis) and distant recurrence (any 
site other than local). 
Statistical analysis
The primary interest of this analysis was to examine 
survival of women with intermediate-risk stage IB 
cervical cancer who received systemic chemotherapy 
compared to those who received CCRT. The secondary 
interest of analysis was to assess recurrence patterns 
based on adjuvant therapy types. A sensitivity analysis was 
performed to examine cases with at least two intermediate-
risk factors by adopting the NCCN guidelines [6]. In 
addition, another sensitivity analysis was performed to 
compare survival of the CCRT group to the RT alone 
group per an ongoing phase III clinical trial examining 
intermediate-risk cervical cancer (GOG-263) [17]. 
Similarly, a sensitivity analysis was performed to examine 
survival of the systemic chemotherapy group compared 
to the RT alone group as radiotherapy alone is the current 
standard adjuvant therapy for patients in the  intermediate-
risk group [4]. 
The statistical significance of continuous variables 
among multiple groups was assessed by either the one-
way ANOVA test or by the Kruskal-Wallis H test as 
appropriate. Statistical significance of categorical and 
ordinal variables was assessed by the chi-square test. The 
Kaplan-Meier method was used to construct survival curves 
and cumulative risk curves [23], and statistical significance 
between these curves was determined by the log-rank test. 
Cox proportional hazard regression models were used to 
assess the independent association of adjuvant therapy and 
survival by adjusting for a priori survival factors [24]. In 
this study, we tested three different models. The first model 
was adjusted for age alone (< 50 versus ≥ 50 years), the 
second model was adjusted for age and histology type 
(squamous versus non-squamous), and the third model 
was adjusted for age, histology, and histo-pathological 
factors (tumor size, depth of myometrial tumor invasion, 
and LVSI). The magnitude of statistical significance was 
expressed with an adjusted-HR and 95% CI. 
We also performed a propensity score matching 
to adjust the background differences between the 
chemotherapy group and the CCRT group. Propensity 
score for chemotherapy use was computed for each case 
determined by multivariable logistic regression analysis. 
In the model, year of diagnosis, age, stage, histology 
types, extent of lymphadenectomy and tumor factors (deep 
stromal invasion, tumor size, and LVSI). An automated 
algorithm was used for one-to-one matching between the 
two groups (cutoff, 1%).
All statistical analyses were based on two-side 
hypothesis, and a P-value of less than 0.05 was considered 
significant. Statistical Package for Social Sciences (IBM 
SPSS, version 24.0, Armonk, NY, USA) was used for 
the analysis. The STROBE guidelines for a retrospective 
observational study were consulted to outline this study [25].
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